Cd274, also known as Programmed cell death ligand 1 (PD-L1), is an essential immune checkpoint protein. It binds to programmed death 1 (PD-1) on T-lymphocytes. The binding inhibits T cell proliferation and activity, enabling cancer cells to escape immune surveillance through tumor immunosuppression [4].

A large meta-analysis including 57,322 patients from 250 studies suggested that CD274 (PD-L1) overexpression was associated with worse overall survival in non-small cell lung cancer, hepatocellular carcinoma, pancreatic cancer, renal cell carcinoma, and colorectal cancer [1]. In colorectal cancer, CD274 on immune cells was associated with good prognosis, while on tumor cells, the outcomes were heterogeneous and it did not meet the requirements of a prognostic marker [2]. Baicalein, a monomer of traditional Chinese medicine, can target CD274 and induce its autophagic-lysosomal degradation, inhibiting tumor development by boosting T-cell-mediated antitumor immunity [3].

In conclusion, Cd274 plays a crucial role in tumor immunosuppression. The studies on Cd274 contribute to understanding its role in multiple cancers, such as non-small cell lung cancer, hepatocellular carcinoma, etc. These findings may provide potential directions for cancer prognosis assessment and immunotherapy development [1,2,3].

References:

1. Park, Ji Hyun, Luchini, Claudio, Nottegar, Alessia, Lim, Beom Jin, Smith, Lee. 2023. Effect of CD274 (PD-L1) overexpression on survival outcomes in 10 specific cancers: a systematic review and meta-analysis. In Journal of clinical pathology, 76, 450-456. doi:10.1136/jcp-2023-208848. https://pubmed.ncbi.nlm.nih.gov/37130750/

2. Alexander, Peter G, McMillan, Donald C, Park, James H. 2020. A meta-analysis of CD274 (PD-L1) assessment and prognosis in colorectal cancer and its role in predicting response to anti-PD-1 therapy. In Critical reviews in oncology/hematology, 157, 103147. doi:10.1016/j.critrevonc.2020.103147. https://pubmed.ncbi.nlm.nih.gov/33278675/

3. Hao, Bingjie, Lin, Shumeng, Liu, Haipeng, Xia, Qing, Fan, Lihong. 2024. Baicalein tethers CD274/PD-L1 for autophagic degradation to boost antitumor immunity. In Autophagy, 21, 917-933. doi:10.1080/15548627.2024.2439657. https://pubmed.ncbi.nlm.nih.gov/39710370/

4. Gou, Qian, Dong, Chen, Xu, Huihui, Shi, Juanjuan, Hou, Yongzhong. 2020. PD-L1 degradation pathway and immunotherapy for cancer. In Cell death & disease, 11, 955. doi:10.1038/s41419-020-03140-2. https://pubmed.ncbi.nlm.nih.gov/33159034/